Insight, China's Pharmaceutical Industry

European Commission Approves Sanofi’s Subcutaneous Sarclisa (Isatuximab) Across All Multiple Myeloma Indications Based on Phase III IRAKLIA Data

The European Commission announced this week its approval of Sanofi’s (NASDAQ: SNY) Sarclisa (isatuximab) subcutaneous...

Company Drug

Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

Fineline Cube Jun 9, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug...

Company

Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments

Fineline Cube Jun 9, 2026

Bayer AG (ETR: BAYN) announced today a strategic leadership restructuring within its Consumer Health division,...

Company Drug

RemeGen Secures Dual NMPA Approvals for Tai’ai (Telitacicept) in Sjögren’s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS/APRIL Inhibitor Franchise

Fineline Cube Jun 9, 2026

RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China’s National Medical Products Administration...

Company Deals

Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation

Fineline Cube Jun 9, 2026

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced today its strategic acquisition of a 30% stake...

Company Drug

Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors

Fineline Cube Jun 9, 2026

Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...

Company Drug

Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data

Fineline Cube Jun 9, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China’s National Medical Products Administration (NMPA)...

Company Drug

Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data

Fineline Cube Jun 9, 2026

Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced today that China’s National Medical Products Administration (NMPA)...

Company Deals

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

Fineline Cube Jun 9, 2026

Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...

Company Deals

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

Fineline Cube Jun 9, 2026

Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China-based Clinical Research Organization (CRO), announced...

Company Drug

Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations

Fineline Cube Jun 9, 2026

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...

Company Drug

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

Fineline Cube Jun 9, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today...

Company Deals Drug

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

Fineline Cube Jun 9, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...

Company Deals

Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology

Fineline Cube Jun 9, 2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive...

Others

GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio

Fineline Cube Jun 9, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026

PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61...

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Fineline Cube Jun 8, 2026

Sino Medical Sciences Technology Inc. (SHA: 688108) announced it has received marketing approval from Colombia’s...

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026

Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at...

Insight, China's Pharmaceutical Industry

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

European Commission Approves Sanofi’s Subcutaneous Sarclisa (Isatuximab) Across All Multiple Myeloma Indications Based on Phase III IRAKLIA Data

Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments

RemeGen Secures Dual NMPA Approvals for Tai’ai (Telitacicept) in Sjögren’s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS/APRIL Inhibitor Franchise

Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation

Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors

Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data

Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology

GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

You Missed

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China